Biliary Tract Cancer Investigator-Initiated Trial
Combination therapy of nanvuranlat and immune checkpoint inhibitors
An investigator-initiated trial evaluating combination therapy with nanvuranlat and an immune checkpoint inhibitor (ICI) for first-line treatment of biliary tract cancer was initiated by the Cancer Institute Hospital of JFCR in May 2026. This trial will evaluate the efficacy and safety of adding nanvuranlat in patients who have received gemcitabine + cisplatin + durvalumab combination therapy and transition to durvalumab monotherapy as maintenance therapy.
＊Durvalumab (anti–PD-L1 antibody) + gemcitabine + cisplatin
Exam progress
In April 2026, the trial was registered and made publicly available on jRCT, Japan’s Clinical Research Registration and Publication System.